Navigation Links
Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimer's Immunotherapy Programs
Date:11/8/2011

482; technology is a proprietary Alzheimer's vaccine with therapeutic and prophylactic potential.   The company's CONJUMAB-A platform is based on antibody drug conjugates with potential applications to treat a broad spectrum of proteinopathies including Alzheimer's disease, Early-Onset Familial Alzheimer's disease, cerebral angiopathy, age-related macular degeneration, glaucoma and traumatic brain injury. IN-N01-OX2 is the company's most advanced internal candidate, a humanized monoclonal antibody targeting beta amyloid conjugated to a naturally occurring small drug molecule with potent neuroprotective properties.  Thus, IN-N01-OX2, incorporates combined features of the ANTISENILIN and CONJUMAB-A platform technologies. The company recently licensed OX1 a small molecule multimodal antioxidant to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases.

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including, without limitation, those  regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements,
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
3. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
7. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
8. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
9. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
10. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
11. Limited Healthcare Infrastructure and Weak Intellectual Property Protection are Among the Challenges Pharma Faces with Emerging Market Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid ... endpoint of improved insulin sensitization in a 6 week ... patients with nonalcoholic fatty liver disease (NAFLD). , By ... that a single oral daily dose of INT-747 statistically ...
... , ST. PAUL, Minn., Oct. 1 Algos Therapeutics ... today announces the selection of Dr. Ganesh Iyer as ... his new responsibilities immediately. , "We were incredibly fortunate ... Dr. Iyer to lead Algos," stated Gary Smaby, Algos ...
Cached Medicine Technology:Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease 2Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO 2
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... “Today, we introduce our new items ... over the world. All these models are offered at ... the UK market,” says the CEO of the company. ... women’s special occasion outfits. , Ladies have to find ... is one of the best choices for many ladies ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides key ... provides value, in millions of US dollars, volume (in ... segments – Rigid Non-Video Sinuscopes. , The report also ... of these market categories, and global corporate-level profiles of ... deals related to the Sinuscopes market wherever available. , ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... to be filed in U.S. courts, Bernstein Liebhard LLP ... federal health regulators to ban uterine morcellation. According to ... a 46-year-old mother of four from California who was ... cancer called leiomyosarcoma just 10 days after undergoing a ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... of two titles, Journal of Analytical Toxicology ( JAT ... from Preston Publications, in a transaction managed by DeSilva+Phillips. The ... STM journal list published by OUP. "We are ... two titles. They have a rich history and we look forward ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- The ... a handy jet at your disposal, but the job also comes ... your life? Maybe not, new research suggests. The data showed ... years off their lives due to the effects of time spent ...
... HOBOKEN, NJ Keeping your brain in shapeno sweat. ... diet is just as important to maintaining mental performance ... are an easy, effective way to manage mental focus, ... antioxidant plant extract from the bark of the French ...
... depressive symptoms following birth also reported intimate partner violence finds ... An International Journal of Obstetrics and Gynaecology . The ... depressive symptoms first reported this at six months after birth ... emotional abuse) in the perinatal period is associated with a ...
... , TUESDAY, Dec. 6 (HealthDay News) -- New ... and when women with certain breast cancers will experience ... forms of breast cancer, are slated to be presented ... The research also revealed that genetic data gleaned ...
... in India are too poor to afford pacemakers. But a ... the devices and implanting them in Indian patients "is very ... Medical Center is a co-author of the study, published online ... . Kulkarni helped conduct the research before coming to Loyola ...
Cached Medicine News:Health News:Oxford University Press acquires 2 journals from Preston Publications 2Health News:Most U.S. Presidents Live Longer Than Their Peers 2Health News:Pycnogenol® found to improve memory and test scores in college students in new clinical trial 2Health News:Depressive symptoms and intimate partner violence in the 12 months after childbirth 2Health News:New Tests Might Better Predict Breast Cancer's Return 2Health News:New Tests Might Better Predict Breast Cancer's Return 3Health News:New Tests Might Better Predict Breast Cancer's Return 4Health News:Reusing pacemakers from deceased patients is safe and effective, study finds 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: